Patents by Inventor Julien ROSSIGNOL

Julien ROSSIGNOL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11872068
    Abstract: The X-ray imager combines a pulsed X-ray source with a time-sensitive X-ray detector to provide a measure of ballistic photons with a reduction of scattered photons. The imager can provide a comparable contrast-to-noise X-ray image using significantly less radiation exposure than conventional X-ray imagers, notably about half of the radiation.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 16, 2024
    Inventors: Rejean Fontaine, Julien Rossignol, Yves Bérubé-Lauzière
  • Publication number: 20220073626
    Abstract: Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells QI predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g.
    Type: Application
    Filed: January 2, 2020
    Publication date: March 10, 2022
    Inventors: Olivier HERMINE, Julien ROSSIGNOL, Zakia BELAID-CHOUCAIR, Guillemette FOUQUET, Lucile COURONNE, Michael DUSSIOT, Rachel RIGNAULT-BRICARD, Tereza COMAN, Flavia GUILLEM, Yves LEPELLETIER, Amédée RENAND, Pierre MILPIED
  • Publication number: 20220008514
    Abstract: The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.
    Type: Application
    Filed: November 28, 2019
    Publication date: January 13, 2022
    Inventors: Tereza COMAN, Francine COTE, Olivier HERMINE, Guillemette FOUQUET, Julien ROSSIGNOL
  • Publication number: 20210369222
    Abstract: The X-ray imager combines a pulsed X-ray source with a time-sensitive X-ray detector to provide a measure of ballistic photons with a reduction of scattered photons. The imager can provide a comparable contrast-to-noise X-ray image using significantly less radiation exposure than conventional X-ray imagers, notably about half of the radiation.
    Type: Application
    Filed: October 29, 2019
    Publication date: December 2, 2021
    Inventors: Rejean FONTAINE, Julien ROSSIGNOL, Yves BÉRUBÉ-LAUZIÈRE
  • Patent number: 10947323
    Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: March 16, 2021
    Assignees: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (INSERM), Assistance Publique—Hopitaux De Paris, Université De Paris
    Inventors: Matthieu Sollogoub, Vincent Calvez, Anne-Geneviève Marcelin, Laurent Bouteiller, Mickaël Menand, Pierre Evenou, Adélie Gothland, Dmitri Colesnic, Julien Rossignol
  • Publication number: 20200010576
    Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.
    Type: Application
    Filed: September 5, 2016
    Publication date: January 9, 2020
    Applicants: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (INSERM), Assistance Publique - Hopitaux De Paris, Universite Paris Descartes
    Inventors: Matthieu SOLLOGOUB, Vincent CALVEZ, Anne-Geneviève MARCELIN, Laurent BOUTEILLER, Mickaël MENAND, Pierre EVENOU, Adélie GOTHLAND, Dmitri COLESNIC, Julien ROSSIGNOL